As oncology continues to evolve toward precision medicine and multi-mechanism synergy, antibody-drug conjugates (ADCs) are emerging as a critical bridge between targeted therapy and cytotoxic treatment. Among them, HLX43, an innovative PD-L1-targeted ADC, stands out for its unique properties: it does not fully rely on T cells, does not depend on microtubule mechanisms, and features a high-affinity antibody design. These characteristics offer a new therapeutic strategy for treating tumors in complex microenvironments.

---

Limitations of PD-L1-Targeted Therapies and the Need for Innovation

PD-L1, a classic immune checkpoint molecule, is a key target in modern cancer immunotherapy. However, traditional PD-1/PD-L1-based therapies (such as immune checkpoint inhibitors) have notable limitations:

● Dependence on intact T-cell function
● Reduced efficacy in immunosuppressive tumor microenvironments
● Limited effectiveness in patients with low PD-L1 expression (e.g., TPS <1%)
● Risk of acquired resistance

These challenges highlight that “immune activation alone” is insufficient to benefit all patient populations, creating a need for new therapeutic approaches.

---

HLX43: Redefining PD-L1-Targeted ADCs

HLX43 is an ADC that combines a high-affinity anti-PD-L1 antibody with a novel cytotoxic payload. Its design reflects three major innovations:

1️⃣ Not Fully Dependent on T Cells

Unlike traditional immune checkpoint inhibitors, HLX43 does not rely entirely on T-cell-mediated immune responses.

Even in cases of T-cell exhaustion, dysfunction, or highly immunosuppressive tumor environments, it may still exert antitumor activity.

---

2️⃣ Independent of Microtubule Mechanisms

Most conventional ADCs use microtubule inhibitors (such as taxanes), which often lead to drug resistance.

● HLX43 employs a non-microtubule-dependent cytotoxic payload, which means:
It can bypass resistance to paclitaxel and docetaxel
● It may remain effective in heavily pretreated patients
● It expands the potential patient population for ADC therapy

This feature makes HLX43 particularly valuable in drug-resistant tumors.

---

3️⃣ High-Affinity Antibody Design

The antibody component of HLX43 exhibits strong binding affinity to PD-L1, offering two key advantages:

● Effective targeting even in tumors with low PD-L1 expression (TPS <1%)
● Enhanced uptake of the ADC by tumor cells

This suggests HLX43 may overcome the traditional dependence on PD-L1 expression levels.

---

Mechanism of Action: Multi-Pathway Tumor Killing

The antitumor activity of HLX43 can be summarized as a “three-in-one” mechanism:

🔬 Precise Targeting
High-affinity antibody binds to PD-L1-expressing tumor cells, including low-expression populations

💊 Cytotoxic Effect
After internalization, the ADC releases a non-microtubule payload that directly induces tumor cell death

🔄 Immune Modulation Potential
Blocking the PD-L1 pathway may partially restore immune system activity

In essence, HLX43 is not just a “killing tool,” but also a “tumor microenvironment regulator.”

---

Unique Advantages in Complex Tumor Settings

HLX43 is designed to perform in scenarios where traditional therapies often fall short:

✔ T-cell dysfunction
(e.g., immune-cold tumors or immunosuppressive environments)
👉 Can still directly kill tumor cells via ADC mechanism

✔ Chemotherapy resistance (paclitaxel/docetaxel)
👉 Non-microtubule mechanism avoids cross-resistance

✔ Low PD-L1 expression (TPS <1%)
👉 High-affinity antibody improves targeting efficiency

✔ Heavily pretreated patients
👉 Provides a novel mechanism of action

---

Comparison with Conventional Therapies

Dimension	Traditional PD-1/PD-L1 Antibodies	Traditional ADCs (Microtubule-based)	HLX43
T-cell dependence	High	Low	Low
Microtubule dependence	No	Yes	No
Efficacy in low PD-L1 tumors	Limited	Moderate	Stronger
Resistance profile	Immune escape	Chemotherapy resistance	Reduced via novel mechanism
Mode of action	Immune activation	Cytotoxic killing	Dual-mechanism synergy

HLX43 represents a new paradigm combining immune modulation + cytotoxicity + high-affinity targeting.

---

Future Development Potential

As ADC technologies continue to evolve, HLX43 may play an important role in:

● Combination therapies with immune checkpoint inhibitors
● Treatment of low-expression or immune-cold tumors
● Expansion into multiple solid tumor indications
● Serving as an option after resistance to standard therapies

Its core significance lies in transforming PD-L1 from a purely “immune target” into a direct therapeutic target.

In this process, platforms like DengYueMed—with strengths in global resource integration and compliant access—can help accelerate the availability of such innovative therapies to broader patient populations worldwide.

---

Conclusion

The emergence of HLX43 marks a new stage in PD-L1-targeted therapy—from reliance on immune activation to direct, multi-mechanism tumor intervention.

By eliminating dependence on T cells and microtubule pathways, and leveraging high-affinity targeting, HLX43 offers new possibilities for patients with immunosuppressive tumors, chemotherapy resistance, and low PD-L1 expression.

As precision oncology continues to advance, innovative ADCs like HLX43—characterized by “mechanism independence”—are likely to become key components in the future landscape of cancer treatment.